CervoMed (CRVO) Common Equity (2010 - 2026)
CervoMed (CRVO) posted Common Equity of $10.6 million for Q1 2026, down 41.75% sequentially from $18.2 million in Q4 2025, and down 69.35% YoY from $34.6 million in Q1 2025.
CervoMed (CRVO) Common Equity (2010 - 2026) Analysis & Trends
CervoMed has reported Common Equity for 17 years, with the latest figure at $10.6 million in Q1 2026.
- Quarterly Common Equity fell 69.35% year-over-year to $10.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.6 million (down 69.35% YoY) and the FY2025 annual result came in at $18.2 million, down 53.52% from the prior year.
- Common Equity slipped to $10.6 million in Q1 2026 per CRVO's latest filing, from $18.2 million in the prior quarter.
- Over five years, Common Equity peaked at $109.3 million in Q2 2024 and troughed at -$35.1 million in Q2 2023.
- A 5-year average of $12.5 million and a median of $14.4 million in 2025 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2024: Common Equity tumbled 210.22% in 2023, then surged 431.43% in 2024.
- Over 5 years, Common Equity stood at -$33.3 million in 2022, then soared by 122.16% to $7.4 million in 2023, then soared by 431.43% to $39.2 million in 2024, then tumbled by 53.52% to $18.2 million in 2025, then sank by 41.75% to $10.6 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $10.6 million, $18.2 million, and $26.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.92 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.57 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.12 Bn | 53.98 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.75 Bn | 28.45 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.72 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.20 Bn | 26.36 Bn | - | 9.79 Bn |
| 10 | CervoMed | 27.05 Mn | 27.05 Mn | - | 22.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.96 Mn |
| Mar 31, 2026 | 10.62 Mn |
| Dec 31, 2025 | 18.22 Mn |
| Sep 30, 2025 | 26.01 Mn |
| Jun 30, 2025 | 33.44 Mn |
| Mar 31, 2025 | 34.63 Mn |
| Dec 31, 2024 | 39.20 Mn |
| Sep 30, 2024 | 45.64 Mn |
| Jun 30, 2024 | 109.26 Mn |
| Dec 31, 2023 | 7.38 Mn |
| Sep 30, 2023 | 9.57 Mn |
| Jun 30, 2023 | -35.11 Mn |
| Mar 31, 2023 | -33.75 Mn |
| Dec 31, 2022 | -33.29 Mn |
| Sep 30, 2022 | -31.84 Mn |
| Jun 30, 2022 | -31.04 Mn |
| Mar 31, 2022 | 30.62 Mn |
| Dec 31, 2021 | -27.94 Mn |
| Sep 30, 2021 | 38.13 Mn |
| Jun 30, 2021 | 50.17 Mn |